Skip to main content

Windtree Therapeutics Inc

WINT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000946486

No open-market purchases or sales by Windtree Therapeutics Inc insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Windtree Therapeutics Inc changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of WINT: Q4 2024 compared with Q1 2025
MeasureQ4 2024Q1 2025Change
Holders155−10
Shares313.7K45.3K−268.4K (−85.6%)
Value$108.7K$57.0K−$51.7K (−47.5%)

New holders (1)

Institutions that held Windtree Therapeutics Inc at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to WINT in Q1 2025
InstitutionSharesValue% of portfolio
Morgan Stanley15,000$18.9K0.00%

Sold out (11)

Institutions that held Windtree Therapeutics Inc at the end of Q4 2024 and filed for Q1 2025 without it.

Institutions that sold out of WINT in Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Renaissance Technologies LLC119,266$41.7K
Geode Capital Management, LLC59,167$20.7K
XTX Topco Ltd19,456$6.80K
Two Sigma Investments, LP14,449$5.05K
Cubist Systematic Strategies, LLC13,696$4.78K
Goldman Sachs Group Inc12,326$4.30K
HRT Financial LP11,057$3.00K
BlackRock, Inc.6$2
Activest Wealth Management2$1
Wells Fargo & Company1$0
Royal Bank of Canada2$0